Stakeholders urge FDA to adopt flexible approach for psychedelic drug regulation

Various individuals and groups have submitted comments urging the U.S. Food and Drug Administration to be flexible in regulating psychedelic medicines that could treat major depressive disorder and post‑traumatic stress disorder.

They ask the agency to avoid creating unnecessary barriers to patient access, to promote proper training and credentialing for clinicians, and to allow labeling updates as new knowledge becomes available.

The remarks were filed through a public docket, reflecting a broad coalition seeking both patient access and safety safeguards.